Multicentre Cancer Chemotherapy Group Randomised Trial of Adjuvant Chemotherapy for 'Early' Breast Cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title	Multicentre Cancer Chemotherapy Group Randomised Trial of Adjuvant Chemotherapy for 'Early' Breast Cancer
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Breast cancer
Intervention	Following initial local therapy, surgery with or without radiotherapy, patients are randomised to one of 2 treatment arms: 1. Arm A: Tamoxifen 10 mg twice daily for 12 months. 2. Arm B: A total of eight cycles of multidrug chemotherapy. Cyclophosphamide, vincristine and 5-fluorouracil to be given on day 1 and cyclophosphamide, vincristine and methotrexate on day 8 of each 3 week cycle. 3. Arm C: Multidrug chemotherapy with vincristine, methotrexate, chlorambucil and 5-fluorouracil repeated every 3 weeks for 8 cycles.
Intervention type	Drug
Phase	Not Applicable
Drug / device / biological / vaccine name(s)	Tamoxifen, cyclophosphamide, vincristine, 5-fluorouracil, methotrexate, chlorambucil
Primary outcome measure(s)	Not provided at time of registration
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	31/12/2005

Participant type(s)	Patient
Age group	Adult
Sex	Female
Key inclusion criteria	1. Aged <70 years 2. Operable primary breast cancer with tumour <5 cm in greatest diameter 3. Histologically proven axillary nose involvement 4. Adequate renal and liver function 5. No prior history of other malignant disease 6. No previous chemotherapy
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/01/2000
Date of final enrolment	31/12/2005

MRC Clinical Trials Unit

London
NW1 2DA
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes

18/01/2016: no publications found on PubMed.